RoosterBio has announced a new collaboration with Thermo Fisher Scientific aimed at speeding up the development and manufacturing of cell and exosome therapies – treatments that could potentially transform the way degenerative diseases are treated.

The partnership, revealed today, will combine RoosterBio’s expertise in mesenchymal stem/stromal cells (hMSCs) with Thermo Fisher’s global contract manufacturing services. The companies say this alliance will give biopharma firms a “comprehensive solution” for bringing new therapies into clinical trials more quickly.

RoosterBio, based in Frederick, Maryland, supplies adult hMSCs, engineered media, and process development tools for companies working on advanced therapies. The firm has developed a portfolio that includes off-the-shelf hMSC products and exosome platforms designed to help biopharma partners avoid early-stage bottlenecks in development.

Thermo Fisher, a multinational leader in science services and manufacturing, will contribute its GMP (good manufacturing practice) expertise—covering everything from cell expansion and purification to final drug product manufacturing. The collaboration allows customers to access an integrated system from early R&D through to clinical-grade production.

“Biopharmaceutical companies striving to develop engineered cell and exosome therapies require proven, flexible technologies paired with reliable and scalable manufacturing capabilities,” said Tim Kelly, CEO of RoosterBio.

“Through this collaboration, we will deliver that comprehensive solution to our customers, and I am delighted to work with Thermo Fisher to translate our MSC and exosome technologies into advanced therapy products for patients around the world.”

Ben Castro, vice president and general manager of large molecule pharma services at Thermo Fisher, added: “Our collaboration with RoosterBio reflects our shared commitment to helping life-changing therapies reach patients in need, in the safest, fastest and most effective way possible.”

The companies note that cell-based therapies—including those that rely on exosomes, the tiny particles cells use to communicate—are gaining momentum in the treatment of inflammatory, neurological, and degenerative diseases. However, manufacturing challenges remain one of the biggest obstacles to getting these treatments to patients.

RoosterBio says it maintains high safety and bioethics standards, with all hMSCs sourced under strict guidelines and produced using standardized, well-characterized processes. The company believes these practices are essential for supporting reproducibility and regulatory compliance in therapeutic development.

This collaboration follows a broader trend in the cell and gene therapy space where partnerships between biotech innovators and global CDMOs are helping to close the gap between early-stage research and clinical access.